Mergers and Acquisitions
Time to Bend My Rules on Viacom by Buying This Sell-Off
Let's go back again to charts of VIAB.
Nvidia Surges on Better-Than-Feared Earnings, Stemming Slide in Semiconductors
Nvidia's second-quarter profits were well below its year-ago earnings but were nicely ahead of analyst expectations.
Tilray Stock Gains Ahead of Highly Anticipated Earnings Release
Tilray will look to sustain a sanguine sentiment on cannabis stocks on Tuesday.
Keurig Dr Pepper Likely to Settle Into Sideways Pattern
Sellers of the beverage company's shares have been acting more aggressively than buyers in recent weeks.
Stay Tuned on Viacom-CBS Deal
A drop in shares doesn't necessarily mean it's time to turn the channel on Viacom, as details of expected merger with CBS will prove 'paramount.'
It's 'Showtime' for Viacom
Armed with Showtime, lots of cartoons and other mainstream shows, the CBS/Viacom merger appears to fit in between Disney Plus' family-friendly shows and Netflix's darker offerings -- but expect some drama for investors.
How to Play the Viacom/CBS Deal, Should There Even Be a Deal
Only at a discount, so if there is disappointment there is some wiggle room for maneuver.
Viacom Creates 2 Interesting Chart Patterns to Keep Traders on Edge
The technical signs do not instill a ton of confidence, though a bit of strength could change the outlook.
Viacom Stock Pops as Media Merger with CBS Set to Close
Viacom shareholders may finally be rewarded this week for their patience.
Why Wall Street Is Still Riding With Uber
Uber's crash on earnings does not mean the stock is totaled according to analysts covering the stock.
Wall Street Says Disney Should Still Be a Winning Stock
Disney's dive after earnings could open up a buying opportunity to investors that missed the recent run.
Tyson Foods Doesn't Turn Tail in Perilous Market After Earnings
The food giant is one of the few stocks holding its ground on Monday morning; here's why.
Interest Lights Up in CannTrust After Talks of Going on the Block
Following growing scandal, CannTrust Holdings is luring bargain shoppers as the stock moves higher after the company announced it's considering selling itself.
What's the Impact of Apple's Intel Deal on Its 5G Plan?
Apple has investors and analysts looking forward to its the 5G future.
While No Magic Pill, Mylan Deal Might Just Revive Drugmaker
The merger with Pfizer's off-patent branded medicines business may be a life-preserver for bulls and provide meaningful expansion across geographical regions while leveraging Pfizer's commercialization capabilities.
Pfizer Deal Might Be Good Treatment for Mylan
But this off-patent tie-up comes with some questions -- such as why are so many Mylan executives hanging on?
A Look at Mylan's New Post-Merger Management
What new management means for Mylan shareholders moving forward.
Mylan Jumps on Deal With Pfizer to Form New Company
Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.
Earnings Volcano Erupts, Locking In on Lam, and Apple-Intel Intel: Market Recon
Also, defense industry names can breathe easier with word of debt ceiling and federal spending deal.
Give Credit to Blue Apron for Partnering With Beyond Meat
The issue is whether it will inspire longer-term customer relationships.
Can FireEye Set Off Its Own Fireworks?
Disappointment in the cybersecurity name could set it up as another takeover candidate.
Broadcom's Interest in Symantec Is All About This One Big Thing
If it wasn't clear before, Broadcom has shifted its focus away from the hardware side of the business in terms of acquisitions.
Buyout Speculation Picks Up in Biotech
Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.
Why Symantec Is a Buy on the Charts
This stock is a buy, if the fine points of the Broadcom offer support more upside.
My 3 Predictions for the Second Half of 2019
Watch the Russell 2000, housing activity, and mergers and acquisitions.
Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.
AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere
The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.
I Believe AbbVie and Allergan Need Each Other
With no other bidder expected to emerge, this is a high risk arbitrage play.
Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015
PFE was ready to pay $160 billion until U.S. regulators blocked the deal.
AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.